A 58-year-old woman has died of a rare neurological condition. The cause of death? Being injected with hormones taken from a corpse.
When you buy through links on our articles, Future and its syndication partners may earn a commission.
A woman in the U.S. has died from severe neurological symptoms that were caused by an abnormal protein — which she was unknowingly injected with nearly 50 years earlier.
Having shown no neurological symptoms in the decades since the injection, the 58-year-old recently began experiencing tremors and changes in her ability to balance while walking. In the following weeks, she developed urinary incontinence, difficulty speaking and abnormal breathing. After being admitted to hospital, she entered a coma and later died, according to a case report published May 14 in the journal Emerging Infectious Diseases.
A follow-up MRI scan while she was in hospital revealed damage to her brain, and further testing showed positive results for an abnormal protein called a prion.
Prions are found in cell membranes, the wall that surrounds every one of our cells, and are thought to be one of the molecules involved in cellular communication and other interactions.
Though prions can exist safely in the body, when these proteins accumulate in the brain they can cause surrounding proteins to contort and "misfold," damaging nerve cells. Infection with an abnormally 'folded' prion from an external source – like eating contaminated meat, as in the case of 'mad cow' disease – can also spark a chain of misfolding in the body.
The brain damage caused by prion diseases is always fatal, with most patients dying within one year of first developing symptoms, according to Mayo Clinic.
In this case, the woman was diagnosed with Creutzfeldt-Jakob Disease (CJD), an extremely rare and fatal brain wasting disease caused by prions.
Related: Here's how dangerous, deadly prions spread to the brain
It is thought the woman was given prion-infected hormones sometime between 1971 and 1980, while receiving treatment for a condition called panhypopituitarism. People with this condition have a lack of hormones produced by the pituitary gland, the organ that secretes a range of hormones including those involved in growth and sexual development.
In the 1970s, panhypopituitarism was treated by injecting patients with human growth hormones extracted from the healthy pituitary glands of people who had died. At the time, this was common practice — as well as being used to treat pituitary conditions, hormones from cadavers were also given to women whose ovaries were not producing eggs.
However, in 1985 researchers identified the first U.S. outbreak of CJD related to treatments with cadaver-derived growth hormones. The treatment was quickly suspended, and later a synthetic alternative hormone, produced by genetic engineering, was approved by the Food and Drug Administration (FDA).
RELATED STORIES
— Alzheimer's comes in at least 5 distinct forms, study reveals
— Shingles vaccine may directly guard against dementia, study hints
— 13 proteins tied to brain aging seem to spike at ages 57, 70 and 78
So far, 0.4% of those treated in the U.S with growth hormones taken from the organs of deceased individuals have gone on to develop CJD. How these hormones were infected with prions is still unknown, and scientists cannot yet explain why there is such a long latency period between the infection and the symptoms arising.
There is currently no treatment available to those with CJD, or any other form of prion disease. However, ongoing research projects seek to uncover treatments for the conditions.
The researchers involved in the recent case study said that while the number of people developing CJD as a result of growth hormone treatment has slowed over the years, it is still possible that new cases will arise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
After her heart started to fail, a first-of-its-kind surgery saved her life
Sue Baker was used to spending time in the hospital. She had started having heart troubles in 2015, and as the issue escalated, she spent more and more time in the hospital. She had a pacemaker implanted to keep her heart beating. Once, she spent five days in a coma. In 2019, as her heart function continued to fail, Baker received a left ventricular assist device, or LVAD, a mechanical pump that helps the heart's left ventricle circulate blood throughout the body. For years, Baker lived on "batteries and electricity," but she didn't stop living her life. She married a man she loved, and they started building a life together in southeast Georgia. However, she knew the LVAD was only a stopgap measure, and wanted to make sure she was living a full life before her health declined further. Four years after getting the LVAD, Baker started having dangerous heart rhythms. She was admitted to the Mayo Clinic in Jacksonville, Florida, and was added to the transplant list to await a new heart. For months, the 58-year-old waited, often receiving painful shocks from her LVAD and pacemaker as they tried to keep her heart functioning. Her body was also producing too many antibodies, which put her at high risk for rejecting any organs she received. Her transplant cardiologist, Dr. Pareg Patel, tested multiple medications, including chemotherapies, to reduce the antibodies. The process was "very scary," she said. One day, Patel came to her with another option: She could have a liver transplant, in addition to the new heart. It might solve the antibody problem. There was just one catch: A heart-liver transplant had never been done in someone with an LVAD before. Her other option was palliative care. "We got to talking about it, and I was like 'You're not going to know unless somebody agrees to do this. There's not much choice, really,'" Baker recalled. "It was going to be an experiment one way or the other." A first-of-its-kind transplant The liver is "like sponges that take down these antibodies," Patel explained. Sometimes, livers are transplanted alongside hearts to lower the risk of rejection. But the procedure means a patient needs to wait until a heart and liver are available from the same donor. Some people die on the waiting list, Patel said. But for Baker, it was the best option. "It's a story where we were able to find an out-of-the-box solution for somebody who I can guarantee you two years ago we would have said no to and put them in hospice," Patel said. "She had less than probably six months to live in, more likely three months." Baker spent months in the hospital, continuing to receive painful shocks from her LVAD and pacemaker. She had other complications, including diagnoses of COVID-19 and pneumonia. In September 2024, she finally received word that a heart and liver were available to her. "I was shocked," Baker said. "I was so excited." Patel said he and his team anticipated that the surgery would be "challenging" and "very high risk" because of Baker's health complications but everyone believed it was the best possible option. Baker would also be donating her "perfectly healthy" liver to another patient, Patel said, in what's known as a domino operation. "I think the cool part of this is for Sue, is that by using this technology, number one, we were able to prove that by placing a liver and a heart from somebody is we're able to make antibodies go close to zero," Patel explained. "And number two, we were able to have Sue become not only a recipient of two organs, but also a donor in the same day." Blazing a path for other patients After her surgery, Baker said she had a long recovery, but spent her time in the hospital bonding with other patients. She tried to be a voice of optimism for other people waiting for transplants, she said. She also received a letter from the person who received her liver. After Baker recovered and left the hospital in October 2024, she was eager to resume her life in Georgia, but tragedy struck: Her husband died from a sudden cardiac arrest just weeks later. Burdened by medical bills and funeral expenses, her financial situation spiraled. She said her housing is now unstable, and most spare money goes to flying to regular check-ups at the Mayo Clinic. A GoFundMe has only raised a few hundred dollars. Patel said Baker will need frequent check-ups and medication to maintain her new organs. Mayo Clinic said it offers financial assistance and payment plan options, as well as financial counseling to patients who are uninsured or underinsured. Baker said she is leaning on her church for emotional support and other aid. She has a caretaker, Charlene, who helps with day-to-day life. She also hopes that her taking part in the first-of-its-kind surgery will allow more people to receive lifesaving treatment, and said the thought brings her some solace. Patel said that another surgery like Baker's was already conducted, and that another is in the works. "If it weren't for her, these other two patients would have no opportunity," Patel said. "Doing what I did, it opened it up for so many more patients," Baker said. "It made me very happy to know that more LVAD patients will be able to go through this and actually have a long chance at life." Iran and Israel exchange fire; Israel intensifies air assault on Gaza Columbia activist Mahmoud Khalil released on bail Trump continues to weigh U.S. intervention in Iran
Yahoo
11 hours ago
- Yahoo
Just 1 dose of magic mushroom compound eases depression for at least 5 years in most patients, small study suggests
When you buy through links on our articles, Future and its syndication partners may earn a commission. DENVER—Psilocybin, the main psychoactive ingredient in magic mushrooms, can alleviate depression for at least five years after a single dose, a new study finds. The research, presented June 18 at the Psychedelic Science 2025 conference in Denver, focused on patients with major depressive disorder (MDD), which is often called clinical depression. The serious mood disorder causes a persistent feeling of sadness and a loss of interest or pleasure in activities that were once enjoyable. The most common treatments for MDD include talk therapy and medications such as selective serotonin reuptake inhibitors, and both can take a long time to show any benefits. When early studies hinted at psilocybin's potential as an antidepressant, a team of researchers undertook the first-ever randomized clinical trial to explore the use of the psychedelic for treating severe depression. The trial included 24 patients, half of whom received psilocybin at the very start of the trial and half of whom received the same dose eight weeks later—the "waitlist" group. Each patient also received 11 hours of psychotherapy. Even in that short time frame, "there was a significant reduction in depression in the immediate-treatment group compared to those on the waitlist," study co-author Alan Davis, director of the Center for Psychedelic Drug Research and Education at The Ohio State University, told Live Science. Once all of the patients had completed the four-week study, the psilocybin appeared to be four times more effective than traditional antidepressant medications, based on previous research data. One month after the treatment, 17 patients had relieved symptoms, including 14 who were in full remission from depression. Patients also responded much faster to psilocybin than is typical for conventional antidepressants. But do these benefits of psilocybin last? Related: Magic mushrooms temporarily 'dissolve' brain network responsible for sense of self Very few long-term studies of psilocybin for depression have been conducted to date, said Dr. Charles Raison, a professor of human ecology and psychiatry at the University of Wisconsin-Madison who was not involved in the research. "They are very difficult to do because people drop out," Raison told Live Science in an email. "But also because they go on all sorts of other treatments that obfuscate the degree to which any longer lasting benefits result from the psychedelic or because the participant got therapy or restarted an antidepressant." To investigate whether the benefits for psilocybin lasted and if the patients had experienced any side effects, the researchers contacted the original trial participants several years later to request their enrollment in a follow-up study. Twenty-one patients enrolled, and their clinicians rated any changes in the participants' levels of depression from before the original treatment to the present day. The patients also filled out a series of self-reported, online questionnaires and met up with clinicians to document their ability to engage in everyday tasks, their levels of anxiety and their general mental health. The researchers assumed that the three patients that didn't sign up for the follow up, and the three that didn't complete the questionnaires had not remained in remission. Even so, the researchers found that 67% of the participants who had suffered from depression half a decade earlier remained in remission after a single psychedelic therapy session. These patients also reported less anxiety and less difficulty functioning on a daily basis. In general, the two-thirds of the patients who responded well reported lasting positive changes in their mindsets, emotional health and relationships. "I'm excited by these deeper aspects of their lives that really speaks to the importance of these interventions beyond just reduction of depression," Davis said. RELATED STORIES —Psychedelics rapidly change the brain. Here's how. —Australia clears legal use of MDMA and psilocybin to treat PTSD and depression —'Magic mushroom' treatment for depression inches closer to approval Most of the patients shared that, following the original treatment, they'd engaged in self-reflection and therapy to help understand themselves and navigate life's challenges. Davis hypothesizes that the psychedelic experience catalyzes a deeper therapy process and would like to conduct future studies comparing the relative influences of psilocybin and psychotherapy in alleviating depression. "The biggest caveat of this study is the small sample size, and the fact that the original trial showed larger antidepressant effects than subsequent larger multi-site studies seem to be showing," Raison said. In a multi-site clinical trial with 233 participants, 37% of the 79 who received a single 25 mg dose of psilocybin, coupled with psychotherapy, went into remission from major depression. While these trials report less widespread antidepressant effects, they support the idea that psilocybin can effectively treat depression, Davis said, and he is keen to see how the findings of multi-site trials hold up five years post-treatment.
Yahoo
11 hours ago
- Yahoo
Vera C. Rubin debut images: How to see the groundbreaking space photos from the world's largest camera
When you buy through links on our articles, Future and its syndication partners may earn a commission. The new Vera C. Rubin Observatory is set to release its debut images — taken with the largest digital camera ever built — on Monday (Jun. 23). The world-first images and videos will be ultra-high-definition and will show off the observatory's highly anticipated, cutting-edge capabilities for the first time. Here's what you need to know. If you want to watch from home, a news conference will be streaming on YouTube in English and Spanish at 11:00 a.m. EDT on Monday. The link to watch is posted on the observatory's website, and is also embedded here. If you'd prefer to bask in the awe of the cosmos with friends, you may be able to attend a watch party near you — or even host one of your own. Groups will gather across the globe in planetariums and universities to admire the highly detailed images and videos as they are released. The observatory has shared links to a map of all registered watch parties, as well as a link to sign up to become a host. During the news conference, the observatory team will introduce the Rubin Observatory before showcasing the new images and discussing their significance. Watch parties may also hear from local scientists and special guests. Be sure to check out the details of a watch party before you attend to learn about any extra programming. The observatory, perched high on a mountain in the Chilean Andes, will peer at interstellar comets and dangerous asteroids, as well as larger objects, like twisting galaxies and exploding supernovas. Related: 'People thought this couldn't be done': Scientists observe light of 'cosmic dawn' with a telescope on Earth for the first time ever Inside Rubin lies the world's largest digital camera and six of the largest optical filters ever produced. Together, they allow researchers to observe different facets of the universe in many wavelengths of light and remarkably high detail. The camera will take a new high-resolution photo of the sky around every 40 seconds. The images will then be transmitted via fiber optic cables to a supercomputer in California, which will analyze the photos. When stitched together, the images can act as a time-lapse video of space, one that is planned to span 10 years. RELATED STORIES —Space photo of the week: Observatory, or alien planet? Boggle your mind with this 360-degree image —Vera C. Rubin Observatory: The groundbreaking mission to make a 10-year, time-lapse movie of the universe —3,200-megapixel camera of the future Vera Rubin Observatory snaps record-breaking 1st photos Using its groundbreaking instruments, the observatory is expected to contribute to current understanding of widely debated phenomena, including dark energy and dark matter — two components that are thought to make up a vast majority of the universe, but remain poorly understood. The new images could be the first of many that vastly improve our understanding of the cosmos. Whether you join a watch party or tune in from the comfort of your couch, these photos are not to be missed.
